Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.54 |
| ▸ | MAP4K3 | Q8IVH8 | 10/20 | 0.53 |
| ▸ | MET | P08581 | 2/20 | 0.53 |
| ▸ | GRK2 | P25098 | 2/20 | 0.53 |
| ▸ | GRK5 | P34947 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.51 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.51 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.51 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18519539 | 0.89 | PIK3CD (0.56) | PIM1PIM2MAP4K3METGRK2 | |
| SCHEMBL10040495 | 0.85 | ALK (0.59) | PIM1PIM2MAP4K3METIRAK4 | |
| SCHEMBL15942449 | 0.85 | MAP4K3 (0.58) | PIM1PIM2MAP4K3METIRAK4 | |
| SCHEMBL3126749 | 0.85 | ALK (0.59) | PIM1PIM2MAP4K3IRAK4CHRNB2 | |
| SCHEMBL2300261 | 0.84 | CHRNB2 (0.66) | MAP4K3METGRK5IRAK4CHRNB2 | |
| SCHEMBL6726843 | 0.84 | IRAK4 (0.58) | PIM1PIM2MAP4K3IRAK4IRAK1 | |
| SCHEMBL29631525 | 0.84 | IRAK4 (0.58) | PIM1PIM2MAP4K3IRAK4IRAK1 | |
| Hydrochloric Acid SCHEMBL20135201 | 0.84 | ALK (0.58) | PIM1PIM2MAP4K3IRAK4CHRNB2 | |
| SCHEMBL15324788 | 0.81 | IRAK4 (0.52) | PIM1PIM2MAP4K3IRAK4CHRNB2 | |
| SCHEMBL14638436 | 0.81 | ALK (0.65) | PIM1PIM2MAP4K3GRK2GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PIM1 442/4885PIM2 389/4885MAP4K3 180/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PIM1 382/4885PIM2 356/4885MAP4K3 148/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | PIM1 442/4885PIM2 389/4885MAP4K3 180/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | PIM1 442/4885PIM2 389/4885MAP4K3 180/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | PIM1 430/4885PIM2 331/4885MAP4K3 203/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PIM1 489/4885PIM2 422/4885MAP4K3 161/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | PIM1 489/4885PIM2 422/4885MAP4K3 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.